share_log

bluebird bio | 10-K: FY2023 Annual Report

bluebird bio | 10-K: FY2023 Annual Report

bluebird bio | 10-K:2023財年年報
美股SEC公告 ·  09/14 04:33

牛牛AI助理已提取核心訊息

bluebird bio, a biotechnology company specializing in gene therapies, reported a net loss of $211.9 million for the year ended December 31, 2023, with an accumulated deficit of $4.3 billion. Despite this, the company saw an increase in product revenue, netting $29.1 million, primarily from U.S. sales of ZYNTEGLO and SKYSONA, and the recent FDA approval of LYFGENIA in December 2023. The cost of product revenue rose to $33.5 million, attributed to increased product sales. Selling, general and administrative expenses also increased by $25.2 million due to higher IT, facility-related costs, and commercial activities for their gene therapies. Research and development expenses decreased by $32.8 million, reflecting a shift of certain expenses to inventory and cost of product revenue following commercialization. The company sold two Priority Review...Show More
bluebird bio, a biotechnology company specializing in gene therapies, reported a net loss of $211.9 million for the year ended December 31, 2023, with an accumulated deficit of $4.3 billion. Despite this, the company saw an increase in product revenue, netting $29.1 million, primarily from U.S. sales of ZYNTEGLO and SKYSONA, and the recent FDA approval of LYFGENIA in December 2023. The cost of product revenue rose to $33.5 million, attributed to increased product sales. Selling, general and administrative expenses also increased by $25.2 million due to higher IT, facility-related costs, and commercial activities for their gene therapies. Research and development expenses decreased by $32.8 million, reflecting a shift of certain expenses to inventory and cost of product revenue following commercialization. The company sold two Priority Review Vouchers in 2022 and 2023, with net proceeds of $102.0 million and $92.9 million, respectively. As of December 31, 2023, bluebird bio had cash and cash equivalents of approximately $221.8 million and expects this to fund operations into the first quarter of 2025. The company's future plans include continued commercialization of ZYNTEGLO, SKYSONA, and LYFGENIA in the U.S., scaling manufacturing capabilities, and conducting clinical studies.
生物技術公司bluebird bio專門從事基因療法,截至2023年12月31日止年度淨虧損達2.119億美元,累計虧損43億美元。儘管如此,該公司的產品收入出現增長,主要來自於ZYNTEGLO和SKYSONA在美國的銷售,以及LYFGENIA在2023年12月獲得FDA批准所帶來的2910萬美元的淨額收入。產品收入成本上升至3350萬美元,歸因於產品銷售增加。由於IT、設施相關成本以及基因療法的商業活動增加,銷售、一般和管理費用也增加2520萬美元。研發費用減少3280萬美元,反映出某些費用在商品化後已轉移到庫存和產品收入成本。該公司於2022年和2023年出售了兩張優先審查券,淨收益分別爲...展開全部
生物技術公司bluebird bio專門從事基因療法,截至2023年12月31日止年度淨虧損達2.119億美元,累計虧損43億美元。儘管如此,該公司的產品收入出現增長,主要來自於ZYNTEGLO和SKYSONA在美國的銷售,以及LYFGENIA在2023年12月獲得FDA批准所帶來的2910萬美元的淨額收入。產品收入成本上升至3350萬美元,歸因於產品銷售增加。由於IT、設施相關成本以及基因療法的商業活動增加,銷售、一般和管理費用也增加2520萬美元。研發費用減少3280萬美元,反映出某些費用在商品化後已轉移到庫存和產品收入成本。該公司於2022年和2023年出售了兩張優先審查券,淨收益分別爲1.02億美元和9290萬元。截至2023年12月31日,bluebird bio擁有大約2.218億美元的現金及現金等價物,並預計可以支持運營至2025年第一季度。該公司未來計劃包括繼續在美國商業化ZYNTEGLO、SKYSONA和LYFGENIA,擴大製造能力,並進行臨床研究。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。